相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab
Marjorie A. Peraza et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2018)
Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10
Michinori Ogura et al.
FUTURE ONCOLOGY (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Lee S. Rosen et al.
TARGETED ONCOLOGY (2017)
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
Wojciech Jurczak et al.
LANCET HAEMATOLOGY (2017)
A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
Richard Markus et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Statistical Primer on Biosimilar Clinical Development
Leah Isakov et al.
AMERICAN JOURNAL OF THERAPEUTICS (2016)
Secondary efficacy results from a phase 3 study comparing efficacy and safety of biosimilar candidate ABP 215 with bevacizumab in patients with non-squamous non-small cell lung cancer (NSCLC)
N. Thatcher et al.
ANNALS OF ONCOLOGY (2016)
ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
N. Cherny et al.
ANNALS OF ONCOLOGY (2016)
A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
Beverly Knight et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
A clinician's guide to biosimilars in oncology
Hope S. Rugo et al.
CANCER TREATMENT REVIEWS (2016)
Biosimilars: Extrapolation for oncology
Giuseppe Curigliano et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience
Theodor Dingermann et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
Kathryn Chapman et al.
MABS (2016)
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
Zhihong Lai et al.
RMD OPEN (2016)
The Emerging Role of Biosimilar Epoetins in Nephrology in the United States
Steven Fishbane et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Clinical considerations for the development of biosimilars in oncology
Mark A. Socinski et al.
MABS (2015)
Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review
Insiya B. Poonawalla et al.
PHARMACOECONOMICS (2015)
Clinical trial development for biosimilars
Rieke Alten et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
C. Jackisch et al.
ANNALS OF ONCOLOGY (2015)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Development and Application of a Robust N-Glycan Profiling Method for Heightened Characterization of Monoclonal Antibodies and Related Glycoproteins
Tanya Q. Shang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Biosimilars entering the clinic without animal studies A paradigm shift in the European Union
Leon A. G. J. M. van Aerts et al.
MABS (2014)
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Biosimilar monoclonal antibodies: a science-based regulatory challenge
Paul J. Declerck
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
Nikos G. Gavalas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Clinical trial design in biosimilar drug development
G. Dranitsaris et al.
INVESTIGATIONAL NEW DRUGS (2013)
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer
Chris Wynne et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer
Judith R. Kroep et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Gustavo Ismael et al.
LANCET ONCOLOGY (2012)
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Steven A. Berkowitz et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy
Pascale Hubert et al.
ONCOIMMUNOLOGY (2012)
Inhibition of VEGF induces cellular senescence in colorectal cancer cells
Mohammad R. Hasan et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis
Tobias Engel Ayer Botrel et al.
LUNG CANCER (2011)
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Martin Schiestl et al.
NATURE BIOTECHNOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Biosimilar therapeutics-what do we need to consider?
Huub d Schellekens
CLINICAL KIDNEY JOURNAL (2009)
Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme
Jeannette R. Flynn et al.
CANCER (2008)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer
Lukas A. Hefler et al.
GYNECOLOGIC ONCOLOGY (2006)
Post-translational modifications in the context of therapeutic proteins
Gary Walsh et al.
NATURE BIOTECHNOLOGY (2006)
Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer
Lee M. Ellis
SEMINARS IN ONCOLOGY (2006)
Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer
T Seto et al.
LUNG CANCER (2006)
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
G. Des Guetz et al.
BRITISH JOURNAL OF CANCER (2006)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vascular endothelial growth factor as a target for anticancer therapy
N Ferrara
ONCOLOGIST (2004)
分享论文
